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ABSTRACT 
A sensitive HPLC method was developed and validated for the estimation of related substances in Brexpiprazole in drug Product. The developed 
method is found to be specific, reproducible, and stability indicating. Kromasil100-5 C18 (150x4.6mm), 5μ column was used and mobile phase 
consisted of mixture of phosphate buffer of pH5.2 and ACN in gradient program is used at a flow rate of 1.0mL/min at a wave length of 215 nm. 
The detector linearity was established from concentrations ranging from LOQ-150% of specification level with a correlation co-efficient of 0.999. 
The method was also validated for specificity, LOD, LOQ, accuracy, robustness, precision. The method is proved to be robust with respect to 
change in flow rate, pH, organic phase composition and column temperature. The proposed method is found to be sensitive, precise, rapid, 
reproducible, and offers good column life. 
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INTRODUCTION 1-3 
Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl] butoxy} 
quinolin-2(1H)-one) is serotonin dopamine activity 
modulator with partial agonist activityat serotonin -1A -(5-
HT1A) and D2 and D3 receptors, combined with potent 
antagonist effect on 5–HT2A, α1B, and α2C adrenergic 
receptors. Brexpiprazole is used in the treatment of 
Alzheimer’s disease, hyperactivity disorder, Post-traumatic 
stress disorder, treatment of bipolar disorder, Adjunctive 
Treatment of Major Depressive Disorder, and Schizophrenia. 
Brexpiprazole is more potent drug than the other class of 
antipsychotic drugs like aripiprazole, therefore lower dose 
used. Brexpiprazole is higher affinity for serotonin 5HT1A 
receptors. Aripiprazole also higher affinity for serotonin 
5HT1A receptors but lesser extent compare to 
Brexpiprazole.  The amount of active pharmaceutical 
substance is more important for activity and potency of drug. 
Stability indicating related substances method is a 
quantitative analytical method based on the structural and 
chemical properties of each active ingredient of a drug 
product. In the present work, intrinsic stability of the drug 
Brexpiprazole was found and a selective, precise and 
accurate RP-HPLC method was developed for Stability 
indicating Related Substances of Brexpiprazole. 
 
Figure 1: Chemical structure of Brexpiprazole 
In the present work, a simple, rapid, precise and sensitive 
reverse phase HPLC method was developed and validated for 
the estimation of Brexpiprazolein pharmaceutical tablet 
dosage form.  
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MATERIALS AND METHODS 4-9 
Instrumental and analytical conditions 
Reagents and chemicals 
The drug Brexpiprazole and its process related impurities 
were gifted by Vimta Labs Ltd. (Hyderabad, India). Buffer 
salts were purchased from Merck and Sigma Aldrich, India. 
Highly purified water for HPLC was obtained from Milli Q 
plus water purifying system, Millipore. Methanol and 
acetonitrile of HPLC grade were obtained from RANKEM, 
India. Mobile phase was vacuum filtered through a 0.45µm 
Polyvinyl Dene Fluoride (PVDF) filter membrane and 
degassed using a sonicator to remove the dissolved gases. 
  
Name of Impurity Structure Classification Chemical Name 
Brexpiprazole 
 
NA (7-{4-[4-(1-benzothiophen-4-
yl] but oxy} quinolin-2(1H)-
one 
Dihydro 
Brexpiprazole 
 
Process 7-(4-(4-(benzo[b]thiophen-4-
yl)piperazin-1-yl)butoxy)-3,4- 
dihydroquinolin-2(1H)-one 
Brexpiprazole N-
Oxide 
 
 
Degradent 7-(4-piperazin-1-yl)butoxy)  
quinnolin-2(1H)-one 
 
N-Alkylated 
Brexpiprazole 
 
Process 7-(4-(4-(benzothiophen-4-
yl)piperazin-1-yl)butoxy)-N-
Methyl  quinnolin-2-one 
O-Alkylated 
Brexpiprazole 
 
Process 7-(4-(4-(benzothiophen-4-
yl)piperazin-1-yl)butoxy)-
8Methyl  quinnolin-2-one 
 
Equipment:  
 Waters e2695 gradient system with Empower-2 software and 2996 module Photo Diode Array detectors equipped with a 
quaternary solvent delivery pump, automatic sample injector and column thermostat was used for the analysis.  
Chromatographic conditions:  
Column                                               : Kromasil 100 5 C-18 (150×46mm,5µ) 
Pump mode                                      :  Gradient 
Flow rate                                           : As per Gradient 
Detection                                           : UV, 215nm 
Column oven temperature           : 35°C 
Injection Volume                             : 50µL 
Run time                                            : 50 minutes 
 
Table 1: Gradient Programme 
Time 
(min) 
Flow 
(ml/min)) 
Mobile Phase-A 
(%v/v) 
Mobile Phase-B 
(%v/v) 
0.01 1.0 75 25 
20.00 1.0 50 40 
30.00 1.0 45 55 
35.00 1.5 25 75 
42.00 1.5 25 75 
43.00 1.0 80 20 
50.00 1.0 80 20 
Rinsing solvent: 100% Methanol (To avoid the carryover) 
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Preparation of analytical solutions 
Preparation of diluent-1 (0.1% Orth phosphoric acid)-
Prepare a required volume by diluting 1 ml of Orth 
phosphoric acid to 1000 ml with mill-Q water and mix well.  
Preparation of diluent-2Prepare a required volume of 
degassed mixture of 0.1% Orth phosphoric acid and 
Methanol in the Ratio of 30:70 v/v. 
Preparation of mobile phase 
Preparation of mobile phase-A Prepare a required volume 
of degassed mixture of pH 5.2 buffer and Acetonitrile in the 
ratio of 95:5v/v 
Preparation of mobile phase-B 
Use degassed Acetonitrile as Mobile Phase-B 
Diluent preparation: Mixture of Water and acetonitrile 
taken in the ratio 50:50 v/v was used as diluent. 
Preparation of the Brexpiprazolestandard solution 
Weigh and transfer accurately about 42 mg of Brexpiprazole 
standard into a 200 ml clean and dry volumetric flask. Add 
about 120 ml of methanol and sonicate to dissolve 
completely for about 15-20 minutes. Dilute to volume with 
diluent-1 and mix well. Transfer 4 ml of above solution into 
100 ml clean, dry volumetric flask, dilute to volume with 
diluent-2 and mix well. Further dilute 3ml above solution to 
100 ml clean, dry volumetric with diluent-2 and mix well. 
Filter through PVDF Millipore or suitable by discarding 
about 5ml of initial solution. 
Preparation of sample solution 
Transfer 10 tablets into a 100 ml clean and dry volumetric 
flask, add about 10ml of diluent-1 and sonicate for about 10 
minutes until all tablets completely disperse, add about 70 
mL methanol and sonicate at room temperature for about 45 
minutes with every 5 minutes intermittent shaking. Make up 
to the volume with diluent-1 and mix. Centrifuge the 
solutions at 5000rpm for 10 minutes. Filter the Supernatant 
solution through finer porosity membrane filter (PVDF-
0.45µ) by discarding about 5 ml initial solution 
Preparation of placebo solution 
Weigh and Transfer the placebo powder equivalent to about 
2.5mg of Brexpiprazole into a 100 ml clean and dry 
volumetric flask, add about 10ml of diluent-1 and sonicate 
for about 10 minutes, add about 70 mL methanol and 
sonicate at room temperature for about 45 minutes with 
every 5 minutes intermittent shaking. Make up to the volume 
with diluent-1 and mix. Centrifuge the solutions at 5000rpm 
for 10 minutes. Filter the Supernatant solution through finer 
porosity membrane filter (PVDF-0.45µ) by discarding about 
5 ml initial solution. 
Method Development and Validation of HPLC 
The proposed analytical method was validated according to 
ICH guidelines (Q2B) with respect to certain parameters 
such as system suitability, specificity, linearity, accuracy, 
precision, robustness and ruggedness.  
Specificity 
The specificity was carried out to determine whether there is 
any interference of any impurities in retention time of 
analytical peak9. The specificity of the method was 
determined by observing the interference of any of the 
possible impurities and excipients.  
Linearity 
The linearity of an analytical procedure is its ability (within a 
given range) to obtain test results which are directly 
proportional to the concentration (amount) of analyte in 
sample. Linearity test solution for the Related Substances 
method was prepared by diluting the stock solution to the 
required concentrations. Five different concentration levels 
of the solutions were prepared in this range from 10% to 
150% of the RS analyte concentration (0.025, 0.050, 0.125, 
0.2520 and 0.376 µg/mL). RSD value for the slope and Y-
intercept of the calibration curve was calculated. Peak area 
under the curve (average peak area of five observations) was 
plotted against the respective concentration level. Straight 
lines were obtained and the calibration equation obtained 
from regression analysis was used to calculate the 
corresponding predicted responses. Y intercepts obtained 
for the drug and other analytes were insignificant.  
Accuracy 
Accuracy is  the closeness of agreement between value which 
is accepted either as a conventional true value or an accepted 
reference value and the value found The accuracy of the 
Related Substances method was evaluated in triplicates at 
three different concentration levels, 50%, 100%, and 150% 
i.e. 0.495,0.990, 1.485 µg/mL in the drug sample. Percentage 
recoveries were calculated from the slope and Y-intercept of 
the calibration curve developed for the drug. Percentage 
recoveries for the drug and impurities were within the range 
90–110%. . 
Precision 
The precision of an analytical procedure expresses the 
closeness of agreement (degree of scatter) between a series 
of measurements obtained from multiple sampling of the 
same homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability 
(same day), intermediate precision (Intraday-Three different 
day, Intraday- different time interval on the same day), and 
reproducibility (different lab). Precision was carried out by 
injecting six replicates at the 100% level. The RSD of the 
peak areas of each impurity was calculated.  
Limit of Detection and quantification 
The LOD is defined as the lowest amount of analyte in a 
sample, but not necessarily quantify as an exact value and 
the LOQ was defined as the lowest amount of analyte in a 
sample  determined with suitable precision and accuracy . 
The LOD and LOQ for Brexpiprazole was determined as a 
S/N ratio of 3:1 and 10:1 respectively by injecting a series of 
dilute solution with known concentration. 
Robustness 
To determine the robustness, three parameters were varied: 
flow rate, pH and percent composition of the organic 
modifier. Deliberate changes in the following parameters 
which affect area of Brexpiprazole and system suitability 
parameters were studied.  
1) Change in % organic phase of mobile phase by ± 5.0%  
2) Change in pH of buffer of water by ± 10% of set pH  
3) Change in the flow rate of the mobile phase by ± 10% of 
the original flow rate 
System Suitability 
System suitability test was used to verify whether the system 
was adequate for the analysis to be performed; it was an 
integral part of chromatographic method development. The 
system suitability parameters were evaluated for the 
developed method by calculating the RSD values of retention 
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time, peak area, asymmetry, and theoretical plates of Six 
standard replicates 
RESULTS AND DISCUSSIONS  
The present investigation reported is a new RP-HPLC 
method development and validation of estimation of 
Brexpiprazole. In order to get the optimized RP-HPLC 
method, various mobile phases and columns were used. 
From several trials final method is optimized with the 
following conditions:     
Linearity 
A series of solutions were prepared using Brexpiprazole 
standard at concentration levels from 1% to 150% of 
standard concentration level and each solution was injected 
into HPLC. Hence the results were obtained within the limit. 
 
Table 2: Linearity values for Brexpiprazolesolution 
%Level Concentration(µg/ml) Area Statistical Analysis 
10 0.025 10749 Slope 446259 
20 0.050 21863 Intercept -777 
50 0.125 54732 Correlation  
Coefficient 
0.999 
100 0.250 110828 
150 0.376 168162 
Table 3: Linearity values for Brexpiprazole N-Oxide 
%Level Concentration(µg/ml) Area Statistical Analysis 
10 0.025 9665 Slope 390208 
20 0.051 19167 Intercept -476 
50 0.126 48783 Correlation  
Coefficient 
0.999 
100 0.253 98388 
150 0.379 148700 
 
       
Figure 2: linearity curve for Brexpiprazole and Brexpiprazole N-Oxide. 
System suitability 
System suitability test was used to verify whether the system was adequate for the analysis to be performed; it was an integral 
part of chromatographic method development. The system suitability parameters were evaluated for the developed method by 
calculating the RSD values of retention time, peak area, asymmetry, and theoretical plates of Six standard replicates. 
Table 4:  System suitability parameters 
Parameter Observation 
 Retention time 13.61 
USP Tailing 1.0 
Plate Count 35790 
%RSD 0.6 
 
Accuracy of the proposed HPLC method 
Sample Solutions were prepared in triplicate using equivalent amount of placebo present in Brexpiprazole Tablets Spiked with 
Known amount of Brexpiprazole drug substance at levels LOQ, 50%,100% and 150% of specification as per test method and 
injected each  solution into HPLC. 
Table 5: Accuracyvalues for Brexpiprazole N-Oxide (for LOQ Level) 
Level Amount added(%w/w) Amount Found(%w/w) % Recovery 
LOQ Level Sample-1 0.0594 0.0543 91.4 
LOQ Level Sample-2 0.0594 0.0602 101.3 
LOQ Level Sample-3 0.0594 0.0575 96.8 
Statistical Analysis 
Mean 96.5 SD 5.0 %RSD 5.2 95%Confidence 
Interval(±) 
12.4 
%Recovery should be between 85.0 and 115.0 for LOQ level and up to 0.2% specification 
y = 390803x 
R² = 0.9999 
0 
50000 
100000 
150000 
200000 
0 0.1 0.2 0.3 0.4 
y = 390803x 
R² = 0.9999 
0 
50000 
100000 
150000 
200000 
0 0.1 0.2 0.3 0.4 
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Table 6: Accuracyvalues for Brexpiprazole N-Oxide (50% to 150% level) 
Level/Sample ID Amount 
Added(%w/w) 
Amount 
Found(%w/w) 
%Recovery Statistical 
Analysis 
50%Level Sample-1 0.495 0.464 93.7 Mean 94.0 
50%Level Sample-2 0.495 0.468 94.5 SD 0.5 
50%Level Sample-3 0.495 0.464 93.7 %RSD 0.5 
100%Level Sample-1 0.990 0.941 95.1 Mean 95.0 
100%Level Sample-2 0.990 0.944 95.4 SD 0.5 
100%Level Sample-3 0.990 0.936 94.5 %RSD 0.5 
150%Level Sample-1 1.485 1.399 94.2 Mean 93.8 
150%Level Sample-2 1.485 1.391 93.7 SD 0.3 
150%Level Sample-3 1.485 1.390 93.6 %RSD 0.3 
Overall Statistical Analysis 
Mean 94.3 SD 0.7 %RSD 0.7 95% 
Confidence(±) 
0.5 
 
%Recovery should be between 85.0 and 115.0. %RSD should not be more than 10.0 for each level. The recovery results indicated 
that the test method has an acceptable level of accuracy for the determination of Related Substance in Brexpiprazole tablets is 
form LOQ to 150% of specification level 
Precision 
The precision of the method was ascertained from determinations of peak areas of six replicates of sample solution and one 
Standard. 
System Precision 
Standard Solutions was prepared as per test method and injected six times into HPLC as per methodology. 
 
 
 
Figure 3: System Precision chromatograms 
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Table 7: System precision values for Brexpiprazole 
RESULTS 
Injection ID Area of Brexpiprazole 
1 113368 
2 113058 
3 112972 
4 112257 
5 112618 
6 112942 
Statistical Analysis 
Mean 112869 
SD 384.4 
%RSD 0.3 
 
 %RSD for the peak areas of Brexpiprazole obtained from six replicate injection of standard solution should not more than 5.0  
Method Precision 
Six Sample Solutions was prepared as per test method and injected into HPLC as per methodology. 
Table 8: System precision values for Brexpiprazole 
RESULTS 
Injection ID Brexpiprazole Brexpiprazole N-Oxide 
%w/w %Recovery %w/w %Recovery 
Sample 1 0.501 100 0.941 95.1 
Sample 2 0.487 97.2 0.943 95.3 
Sample 3 0.493 98.4 0.936 94.5 
Sample 4 0.494 98.6 0.933 94.2 
Sample 5 0.493 98.4 0.924 93.3 
Sample 6 0.495 98.8 0.933 94.2 
Statistical Analysis 
Mean 0.494 98.6 0.935 94.4 
SD 0.004 0.9 0.007 0.7 
%RSD 0.8 0.9 0.7 0.7 
95% Confidence Interval 0.004 0.9 0.007 0.7 
 
%RSD should not be more than 10.0 for the results of Brexpiprazole obtained from the six determinations. % Recovery should 
Between85.0 to 115.0. 
Robustness 
Standard and Sample Solution spiked with known Related Substance at Specification level were prepared as per test method and 
injected into HPLC at different deliberately varied conditions to evaluate method ability to remain unaffected. 
The varied conditions include change in Flow Rate by ±10%, Column Oven Temperature by ±5%°C, Gradient Composition by 
±1%Absolute with respect to Mobile Phase-B, Wavelength by±5nm, Organic Composition in Mobile Phase-A by±1 and pH of the 
Buffer ±0.1 Units. 
 
 
Figure 4: Diluent chromatograms 
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Figure 5: Sample chromatograms (As such) 
 
Figure 6: Sample chromatograms (0.9ml/min) 
 
Figure 7: Standardchromatogram(0.9ml/min 
Table 6: Robustness study of BrexpiprazoleStandard Solution 
Parameter Variation System Suitability 
USP Plate Count USP Tailing 
Flow Rate -10% 35366 1.2 
+10% 30882 1.2 
Column oven -5°C 32504 1.2 
+5°C 32256 1.1 
Wave length -5 nm 32740 1.2 
-5 nm 32465 1.1 
Gradient Composition 
Mobile Phase-A 
-1% Absolute 36684 1.2 
+1% Absolute 30220 1.2 
Gradient Composition 
Mobile +Phase-A 
-1% Absolute 36104 1.2 
+1% Absolute 30556 1.2 
pH of Buffer -0.1 Units 32644 1.2 
+0.1 Units 33874 1.2 
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Table 6: Robustness study of Brexpiprazole Spiked Sample Solution 
Parameter Variation Brexpiprazole     
N-Oxide  
N-Alkylated-7-
Hydroxy 
Carbostyril 
Brexpiprazole Di hydro 
Brexpiprazole 
Flow Rate -10% 0.79 0.87 1.00 1.13 
+10% 0.78 0.86 1.00 1.13 
Column Oven 
Temperature 
-5°C 0.80 0.88 1.00 1.14 
+5°C 0.77 0.84 1.00 1.14 
Wavelength -5nm 0.79 0.86 1.00 1.13 
+5nm 0.79 0.86 1.00 1.13 
Gradient 
Composition 
Mobile Phase-A 
 
-1% Absolute 0.80 0.87 1.00 1.13 
+1% Absolute 0.78 0.86 1.00 1.14 
Gradient 
Composition 
Mobile Phase-B 
-1% Absolute 0.79 0.87 1.00 1.13 
+1% Absolute 0.78 0.86 1.00 1.14 
pH of Buffer -0.1 units 0.81 0.87 1.00 1.13 
+0.1units 0.84 0.84 1.00 1.13 
 
From spiked sample with known related substances 
obtained from different robustness conditions, there Related 
Substances at each varied conditions. 
CONCLUSION 
The developed and validated stability indicating RP-HPLC 
Related Substances method is specific, Sensitive and robust. 
The method found to be advantageous and simple by using 
Gradient elution mode. All the analytical data for all method 
validation parameters tested and found out to be 
satisfactory. The developed method can suitably use by 
quality control department to determine the Related 
substances in commercial and stability test samples of 
Brexpiprazole Tablets. 
REFERENCES 
1. National drug monograph Brexpiprazole (REXULTI®), VA 
Pharmacy Benefits Management Services Medical Advisory 
Panel and VISN Pharmacist Executives, 2016. 
2. ICH- Harmonized Tripartite Guideline, Q1B, Stability Testing: 
Photo Stability Testing of New Drug Substances and products, 
1996. 
3. ICH- Harmonized Tripartite Guideline, Q3A (R1), Impurities in 
New Drug Substance, 2006. 
4. ICH-Harmonized Tripartite Guideline, Q2 (R1), Validation of 
Analytical Procedures: Text and Methodology, 2005. 
5. National Alliance on Mental Illness Mental health by the 
numbers. Available at: www.nami.org/Learn-More/Mental-
Health-By-the-Numbers [accessed on August 16, 2015]. 
6. Das S., Barnwal P., Blessed W.A., Mondal S., Saha I. Ther Adv 
Psychopharmacol. 2016: 6(1):3954. 
7. Wikipedia [internet], [reviewed 2017 Sep 2; cited 2017 Sep 
27]. Avai lable from:htt ps:// en.wi kipedia. org/wik 
i/Brexpiprazole, oct. 4th, 2017. 
8. Sravani A., & Durga C.H.N., Divya U., Suneetha C.H., Suresh P., 
Rao B.T., Sudheer C., Indo Am J Pharm Res.2017: 7: 8560-8565. 
9. ICH Guideline Q2(R1) (1996) on Validation of Analytical 
Procedures: Text an d Methodology, InternationalConference 
on Harmonization, Geneva, 6 Nov 1996. 
 
 
 
 
